У нас вы можете посмотреть бесплатно Cannabis Industry and Cannabinoid Testing Symposium или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
ACS symposiums are made possible by the generosity of our supporters. Your donation helps us keep these conversations going. Please consider giving today: https://www.cannaspecialists.org/donate This symposium, brought to you by the Association of Cannabinoid Specialists, and led by Dr. Julie Johnson, Chief of Research at the Commonwealth of Massachusetts Cannabis Control Commission, delves into the intricacies of cannabis and cannabinoid testing within the regulated industry. Johnson begins by explaining the history of cannabis legalization in Massachusetts, highlighting the roles of the Cannabis Control Commission and the foundational steps leading up to the legalization and regulation of medical and adult-use cannabis. She further discusses the research mandates that monitor the social and economic impacts of cannabis and the public health impact on the state level. The presentation emphasizes the importance of evidence-based policy-making and regulatory practices, tackling topics such as testing standards for various cannabinoids, heavy metals, pesticides, and more. Highlights include analyses of THC and THCA trends and data on total yeast and mold rates. Johnson underscores the critical need for rigorous testing standards to distinguish between regulated and unregulated markets, particularly with the rise of novel cannabinoids like Delta-8 and Delta-10 THC. The event also touches on the challenges faced in cannabis and cannabinoid research due to federal scheduling, advocating for better standardization and regulatory frameworks. The interaction ends with a Q&A session discussing broader implications such as the rescheduling of cannabis under federal law and the public health concerns associated with chemically-derived cannabinoids.